Omadacycline

September had several clinical trial results announcements and a few FDA approvals triggering moves in the space. New molecular moiety, or NME, approvals totalled a mere three in September, taking the total NME approvals for 2018 to 37 compared to 46 in 2017. Here are the PDUFA catalysts for...

Shares of Paratek Pharmaceuticals Inc (NASDAQ: PRTK) soared by more than 30 percent on Wednesday after a Bloomberg report suggested the company is looking to sell itself to a larger peer. Sources close to the matter told Bloomberg that Paratek is still in the exploration phase and is consulting...

Cantor Fitzgerald has raised its price target on the shares of Paratek Pharmaceuticals Inc (NASDAQ: PRTK) to $30 (82 percent upside) from $27 after the company announced positive data from the Phase 3 trial of Omadacycline in acute bacterial skin and skin structure infections (ABSSSI). The...